Insmed Incorporated (LON:0JAV)
145.52
-1.12 (-0.76%)
Feb 12, 2026, 5:08 PM GMT
Insmed Revenue
Insmed had revenue of $142.34M USD in the quarter ending September 30, 2025, with 52.36% growth. This brings the company's revenue in the last twelve months to $447.02M, up 30.34% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$447.02M
Revenue Growth
+30.34%
P/S Ratio
69.77
Revenue / Employee
$351.71K
Employees
1,271
Market Cap
23.20B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
| Dec 31, 2018 | 9.84M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 11.50M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 4.42M | -2.50M | -36.18% |
| Dec 31, 2010 | 6.92M | -3.45M | -33.28% |
| Dec 31, 2009 | 10.37M | -1.33M | -11.33% |
| Dec 31, 2008 | 11.70M | 4.12M | 54.32% |
| Dec 31, 2007 | 7.58M | 6.56M | 639.61% |
| Dec 31, 2006 | 1.03M | 894.00K | 682.44% |
| Dec 31, 2005 | 131.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Insmed News
- 20 days ago - Roth Capital Initiates Coverage on Insmed (INSM) with Buy Rating | INSM Stock News - GuruFocus
- 20 days ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 20 days ago - Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts - CNBC
- 21 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM - PRNewsWire
- 22 days ago - RBC Capital Raises Price Target for Insmed (INSM) to $200 | INSM Stock News - GuruFocus
- 22 days ago - GraniteShares Advisors LLC Buys 174 Shares of Insmed Inc (INSM) - GuruFocus
- 22 days ago - Park Capital Management, LLC / WI Buys 5,989 Shares of Insmed Inc (INSM) - GuruFocus
- 23 days ago - Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity - Seeking Alpha